药学SCI论文翻译
A、B周期分别纳入病例154例和180例,其中多数研究对象为女性,两周期的女性患者比例分别为98(63.64%)和119(66.11%)。两周期均未出现新生儿及婴幼儿患者,两周期患者平均年龄分别为41.9±16.1岁,和40.6±14.2岁,老年患者(年龄>60周岁)分别占43例(27.92%)和54例(30.00%)。 两周期的临床资料比较无统计学差异( P>0.05) 具有可比性。虽然该药物的使用与患者的体重明确的关联性,在所有病历中均详细登记了患者的体重。
The number of patients included in Group A and B were 154 and 180, respectively. The averaged ages for group A and B were 41.9±16.1 yrs and 40.6±14.2 yrs, respectively. Most of the patients were female (group A: 63.64%, group B: 66.11%). No significant difference was noted between the clinical data before the study.
A、B两周期按照DUE标准适应症使用的患者分别有119例(77.27%)和168例(93.33%),具体适应症见表2。A、B周期有明显禁忌症而使用该药物情况分别为18例(11.69%)和12例(6.67%),主要都是因患者有药物过敏史或过敏体质而使用参麦注射液。虽然A、B两周期在适应症选择和禁忌症的使用上都没有达到预设的标准,通过χ2检验,P值均<0.001,说明B周期比A周期在适应症选择和禁忌症的使用方面都有显著性改善。
The number of patients showed the indications of Shenmai injection were 119 (77.27%) and 168 (93.33%), respectively. The number of patients showed the contraindications (mainly due to history of allergy) were 18 and 12 in group A and B, respectively. Compared with Group A, significant improvement was noted in the patients with indications and contraindications of Shenmai injection in Group B (P<0.01).